In an early-phase trial, investigators study whether combining immunotherapies expands “tumor-specific immune activation.” A small phase Ib study of a combination of an investigational cytokine-based immunotherapy and the checkpoint inhibitor pembrolizumab (Keytruda) showed promise...
Researchers seek to understand why some patients do not respond to immunotherapeutics while others achieve durable outcomes.
The FDA added lenvatinib to the armamentarium for oncologists treating certain patients with renal cell carcinoma.
The FDA approved cabozantinib for treating certain patients with the most common form of kidney cancer diagnosed in U.S. adults—renal cell carcinoma.
The FDA expanded the use of the immune checkpoint inhibitor nivolumab to include certain patients with kidney cancer.
Research is beginning to reveal that the metabolic health problems often associated with being or obese can themselves influence risk for certain cancers.
The FDA recently approved new therapeutics for acute lymphoblastic leukemia, metastatic melanoma, and advanced ovarian cancer. In December 2014, the U.S. Food and Drug Administration (FDA) issued three approvals for new medications to treat...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now